Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticleAccepted Article

Meaningful change thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue and pain interference scores in patients with rheumatoid arthritis

Jennifer L. Beaumont, Elizabeth S. Davis, James F. Fries, Jeffrey R. Curtis, David Cella and Huifeng Yun
The Journal of Rheumatology March 2021, jrheum.200990; DOI: https://doi.org/10.3899/jrheum.200990
Jennifer L. Beaumont
Clinical Outcomes Solutions, Tucson, AZ, USA; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA; Stanford University School of Medicine, Stanford, CA, USA; Division of Immunology and Rheumatology, University of Alabama at Birmingham, irmingham, AL, USA; Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Corresponding author: Huifeng Yun, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth S. Davis
Clinical Outcomes Solutions, Tucson, AZ, USA; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA; Stanford University School of Medicine, Stanford, CA, USA; Division of Immunology and Rheumatology, University of Alabama at Birmingham, irmingham, AL, USA; Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Corresponding author: Huifeng Yun, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James F. Fries
Clinical Outcomes Solutions, Tucson, AZ, USA; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA; Stanford University School of Medicine, Stanford, CA, USA; Division of Immunology and Rheumatology, University of Alabama at Birmingham, irmingham, AL, USA; Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Corresponding author: Huifeng Yun, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey R. Curtis
Clinical Outcomes Solutions, Tucson, AZ, USA; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA; Stanford University School of Medicine, Stanford, CA, USA; Division of Immunology and Rheumatology, University of Alabama at Birmingham, irmingham, AL, USA; Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Corresponding author: Huifeng Yun, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Cella
Clinical Outcomes Solutions, Tucson, AZ, USA; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA; Stanford University School of Medicine, Stanford, CA, USA; Division of Immunology and Rheumatology, University of Alabama at Birmingham, irmingham, AL, USA; Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Corresponding author: Huifeng Yun, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huifeng Yun
Clinical Outcomes Solutions, Tucson, AZ, USA; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA; Stanford University School of Medicine, Stanford, CA, USA; Division of Immunology and Rheumatology, University of Alabama at Birmingham, irmingham, AL, USA; Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Corresponding author: Huifeng Yun, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective We estimated meaningful change thresholds (MCTs) for Patient-Reported Outcomes Measurement Information System (PROMIS®) Fatigue and Pain Interference in rheumatoid arthritis (RA).

Methods The responsiveness of several patient-reported outcomes (PROs) was assessed among 521 RA patients in the Arthritis, Rheumatism, and Aging Medical Information Systems (ARAMIS) cohort. PROMIS Fatigue (7 item) and Pain Interference (6 item) short form instruments were administered at baseline, 6 months, and 12 months. Self-reported retrospective changes over the previous 6 months (a lot better/worse, a little better/worse, stayed the same) were obtained at 6 and 12 months follow-up. We estimated MCTs using the mean change in PROMIS scores for patients who rated their change ‘a little better’ or ‘a little worse.’

Results Baseline fatigue and pain interference scores were near normal (median 54 and 56, respectively). At 6 months, 7.9% of patients reported their fatigue was a little better compared to baseline (mean change [SD]: -2.6 [4.8]), 22.8% a little worse (1.7 [5.6]). Pain was a little better for 11.5% of patients (-1.9 [6.1]) and a little worse for 24.2% of patients (0.6 [5.7]). At 12 months, results were similar. Thus, the MCT range was 1-2 points for both Fatigue and Pain Interference. Correlations between change scores and retrospective ratings were low (0.13-0.29), indicating possible underestimate for MCT.

Conclusion The group-level MCT for PROMIS Fatigue and Pain Interference is roughly 2-3 points and corresponds to a small effect size, which is consistent with earlier work demonstrating a MCT of 2 points for PROMIS Physical Functioning.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 48, Issue 4
1 Apr 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Meaningful change thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue and pain interference scores in patients with rheumatoid arthritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Accepted manuscript
Meaningful change thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue and pain interference scores in patients with rheumatoid arthritis
Jennifer L. Beaumont, Elizabeth S. Davis, James F. Fries, Jeffrey R. Curtis, David Cella, Huifeng Yun
The Journal of Rheumatology Mar 2021, jrheum.200990; DOI: 10.3899/jrheum.200990

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Accepted manuscript
Meaningful change thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue and pain interference scores in patients with rheumatoid arthritis
Jennifer L. Beaumont, Elizabeth S. Davis, James F. Fries, Jeffrey R. Curtis, David Cella, Huifeng Yun
The Journal of Rheumatology Mar 2021, jrheum.200990; DOI: 10.3899/jrheum.200990
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Test-retest reliability for HAQ-DI and SF-36 PF for the measurement of physical function in psoriatic arthritis
  • Psoriasis characteristics for the early detection of psoriatic arthritis
  • Effects of denosumab in Japanese rheumatoid arthritis patients treated with conventional anti-rheumatic drugs: 36-month extension of a phase 3 study
Show more Accepted Article

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire